



BRITISH

MEDICAL JOURNAL



British Medical Journal Volume-1, No 2
10.5281/zenodo.5201509

British Medical Journal

Volume 1, No 2., 2021

Internet address: <http://ejournals.id/index.php/bmj>

E-mail: info@ejournals.id

Published by British Medical Journal

Issued Bimonthly

3 knoll drive. London. N14 5LU United Kingdom

+44 7542 987055

Chief Editor

Dr. Fiona Egea

Requirements for the authors.

The manuscript authors must provide reliable results of the work done, as well as an objective judgment on the significance of the study. The data underlying the work should be presented accurately, without errors. The work should contain enough details and bibliographic references for possible reproduction. False or knowingly erroneous statements are perceived as unethical behavior and unacceptable.

Authors should make sure that the original work is submitted and, if other authors' works or claims are used, provide appropriate bibliographic references or citations. Plagiarism can exist in many forms - from representing someone else's work as copyright to copying or paraphrasing significant parts of another's work without attribution, as well as claiming one's rights to the results of another's research. Plagiarism in all forms constitutes unethical acts and is unacceptable. Responsibility for plagiarism is entirely on the shoulders of the authors. Significant errors in published works. If the author detects significant errors or inaccuracies in the publication, the author must inform the editor of the journal or the publisher about this and interact with them in order to remove the publication as soon as possible or correct errors. If the editor or publisher has received information from a third party that the publication contains significant errors, the author must withdraw the work or correct the errors as soon as possible.

OPEN ACCESS

Copyright © 2021 by British Medical Journal

British Medical Journal Volume-1, No 2

THE SIGNIFICANCE OF HELICOBACTER PYLORI INFECTION IN GASTROINTESTINAL FOOD ALLERGIES IN CHILDREN

Ganieva Shakhzoda Shavkatovna - Assistant of the Department of Pediatrics of the Bukhara State Medical Institute

Turaev Telman Temirovich - Assistant of the Department of Pediatrics of the Bukhara State Medical Institute

Panoyev Xurshid Shuxratovich - Assistant of the Department of Pediatrics of the Bukhara State Medical Institute

Abstract: This review presents the data of modern scientific studies indicating the pathogenetic relationship of *Helicobacter pylori* infection with the gastrointestinal form of food allergy in children. From the position of foreign researchers, the cascade mechanism of the immune response is considered, in the form of an allergic reaction that occurs when the integrity of the gastrointestinal barrier is violated by *Helicobacter pylori* infection. The authors have formulated a conclusion about the spectrum of pathogenicity of the microbe, its dual role in the immune system, as a protective agent and a factor provoking food allergies.

Keywords: *Helicobacter pylori*, gastrointestinal allergy, food allergy, immunity, gastrointestinal tract, children

Introduction: Chronic diseases of the digestive system are among the most common in childhood. The leading etiopathogenetic factor in the formation of inflammatory gastroduodenal pathology is *Helicobacter pylori* infection. Numerous studies in this area have made a significant contribution to understanding the mechanisms of *Helicobacter pylori* persistence in the body [1].

Helicobacter pylori is the most common bacterial infection in the world. The bacteria have the ability to persist in infected individuals for many decades. Over the course of evolution, bacteria have acquired character traits that allow them to evade and destroy both innate and adaptive branches of the immune system to ensure their persistence before the local and systemic immune response [2].

Helicobacter pylori is estimated to be present in the stomach of about half of the world's population. It usually colonizes the gastric mucosa from early childhood, where it persists throughout life if it is not treated with antibiotics. This is the main cause of peptic ulcer and stomach cancer, however, the disease occurs only in 10-15% of cases, and the infection usually remains asymptomatic [3].

In recent years, there has been a tendency to reduce the prevalence of *Helicobacter pylori* infection among children. In their study, Chinese researchers Tang et al. a statistically significant decrease in the level of *Helicobacter pylori* infection in children with symptoms of the disease was reported in the period from 2005 (25.6%) to 2017 (12.8%) in China [4].

The researchers compared the prevalence of active *Helicobacter pylori* infection among children with and without allergies, as well as further analysis of the relationship between various environmental risk factors and the presence of allergies [5].

Many intestinal and extra-intestinal symptoms of most diseases are associated with this infection. *Helicobacter pylori* allows food allergens to access the blood, destroying the gastric mucosa, predisposing to food allergies (PA). Previous studies have considered chronic urticaria as a known symptom of PA and a skin manifestation of *Helicobacter pylori* infection. The *Helicobacter pylori* antigen was detected in the stool of a group of patients complaining of both disorders [6].

Helicobacter pylori has a wide range of pathogenicity factors, in particular cytotoxins, aggression enzymes and factors that provide protection against human immunity. The most well-studied cytotoxin contributing to epithelial cell damage is vacuolizing cytotoxin (VacA) and cytotoxin-associated gene (CagA). To date, it is known that *Helicobacter pylori* induces strong humoral and cellular immune reactions, but they are not able to eliminate the bacterium [7].

In most people, *Helicobacter pylori* infection is asymptomatic, and only a small part develops a stomach ulcer and duodenal ulcer, and if it persists for a long time, lymphoma or stomach cancer. Consequently, a more accurate understanding of the molecular mechanisms of the pathogenesis of *Helicobacter pylori* may allow us to more effectively find ways of eradication [8].

Experimental data obtained on the association of allergies and infections generated in mouse models of allergic diseases show that these disorders do not develop in the presence of *Helicobacter pylori*. And the proposed mechanisms of the protective action of *Helicobacter pylori*, apparently, involve regulators (T-reg) with a high degree of suppressive activity in the induction of T-lymphocytes [9].

Helicobacter pylori affects the immune system by shifting the cytokine balance to the type of T-helper (Th)1, which suppresses allergic diseases that depend on the Th2 cell type, protecting infected individuals from the development of allergic diseases. This may also explain the low prevalence of eosinophilic esophagitis in *Helicobacter pylori*-infected people [10].

According to the results of most studies of the Western world, selective immunoglobulin (Ig) A deficiency is the most common and is associated with the growth of *Helicobacter pylori* - associated diseases. The relationship between atopic bronchial asthma and the ability of *Helicobacter pylori* to modulate the anti-Th2 inflammatory response through activation of the neutrophil protein was studied. In addition, in patients with *Helicobacter pylori* and asthma, there was a decrease in the levels of IgE, interleukin (IL)-4 and IL-13 in the blood serum and an increase in IL-10 and interferon (IFN) - γ compared to the control group [11].

Recent scientific works prove the importance of microbiocenosis of the gastrointestinal tract (gastrointestinal tract) in the process of allergy formation, that the prevalence of *Helicobacter pylori* infection significantly differed between children with and without allergies, and also revealed the role of the interaction of genetic (family history of allergies) and environmental (type of birth, breastfeeding,

previous antibacterial therapy) factors in the development of allergies. Several meta-analyses have demonstrated an inverse relationship between *Helicobacter pylori* infection and allergy. According to the results of these studies, the main confusion regarding the relationship between infection and allergy is associated with many factors that could affect the lower prevalence of infection in allergic children [12-14].

Protective factors of the gastric mucosa, as well as environmental factors and bacterial virulence are associated with the clinical outcome of the disease in *Helicobacter pylori* infection. There have been a limited number of studies examining these interactions, but several studies published last year included pediatric patients and explained new mechanisms of their pathophysiology. Alvarez et al. protective factors of the gastric mucosa and the risk of developing stomach cancer in the presence of *Helicobacter pylori* infection were studied [15].

Chen et al. the effect of *Helicobacter pylori* infection on the gastric mucosa, which causes an inflammatory reaction by producing inflammatory peptides - cytokines, was studied. They observed that IL-6 activates serum exosomes secreted by gastric epithelial cells and promotes the release of the pro-inflammatory cytokine IL-1a, since it is a receptor for the expression of this cytokine [16].

Helicobacter pylori is a risk factor for the development of chronic urticaria and food allergies[17]

Gastrointestinal symptoms may also accompany anaphylactic reactions to food. At the same time, non-IgE-mediated allergic reactions to food, especially isolated gastrointestinal manifestations of allergy in the absence of skin rashes, cause the greatest difficulties in diagnosis [18].

The higher prevalence of *Helicobacter pylori* among patients with allergic diseases, observed in some studies, raised the question of the role of inflammation in the development of allergies. The positive relationship between *Helicobacter pylori* and allergic diseases is still being discussed in relation to PA [19].

Helicobacter pylori causes an inflammatory response as a chronic persistent infection not only inside the stomach, but also causes extraintestinal diseases that require eradication [20].

Helicobacter pylori allows food allergens to gain access to the blood, destroying the gastric mucosa, predisposing to PA. Approximately 20% of the *Helicobacter pylori* microorganisms in the stomach adhere to the surface of the stomach epithelial cells. This physical contact causes damage to epithelial cells, causes inflammation and facilitates the delivery of toxins, which in turn contributes to bacterial invasion and persistence. *Helicobacter pylori* infection is able to trigger an IgE immune response. Studies have found an increase in IgE as a result of increased Th2-type production in frequently ill children [21].

In PA, children had a deep deficiency of CD4+ lymphocytes against the background of an increase in the relative content of lymphocytes with a receptor for apoptosis-CD95+lymphocytes by 1.2 times ($P<0.05$), while the absolute value was increased by 1.3 times ($P<0.05$) [22].

Sang Pyo Lee's research has shown that *Helicobacter pylori* infection has a pathogenetic connection with allergic diseases. *Helicobacter pylori* can provoke the

release of histamine from basophils and, apparently, also suppresses the allergic reaction of the immune response through Th cells. Thus, the results obtained contradict each other, suggesting that *Helicobacter pylori* infection is both associated with the risk of developing allergies and is also a protective factor against allergies [23].

CONCLUSION

1. *Helicobacter pylori* infection in children is clinically different from its manifestations in adults. Along with gastrointestinal diseases, *Helicobacter pylori* in children has extra-intestinal manifestations.

2. The atopic tendency of the immune response in children determines a high level of IdE to *Helicobacter pylori* and a decrease in IdE in the gastrointestinal mucosal barrier, which is manifested by the clinical picture of gastrointestinal allergy.

3. *Helicobacter pylori* induces a higher level of Th1 cellular immune response, which can balance the pro-allergic Th2 response.

4. A reliable way to detect *Helicobacter pylori* is the most important issue that is still being actively discussed. In addition, new diagnostic methods should be better studied in order to reduce healthcare costs and provide patients with less invasive diagnostic alternatives.

References

1. Mazurina S. A., Ilintseva N. V., Agafonov V. E., Gervazieva V. B. Antihelicobacter IgE antibodies in children with diseases of the gastroduodenal zone and concomitant allergopathology *Experimental and clinical gastroenterology* No. 9, 2013 c21-25
2. Arnold I.C, Hitzler I and Müller A (2012) The immunomodulatory properties of *Helicobacter pylori* confer protection against allergic and chronic inflammatory disorders. *Front.Cell.Inf.Microbio.* 2:10. doi: 10.3389/fcimb.2012.00010
3. White JR, Winter JA, Robinson K. Differential inflammatory response to *Helicobacter pylori* infection: etiology and clinical outcomes. *Journal of inflammation research.* 2015;8:137-47.
4. Tang MYL, Chung PHY, Chan HY, Tam PKH, Wong KK. Recent trends in the prevalence of *Helicobacter pylori* in symptomatic children: a 12-year retrospective study in a tertiary centre. *J Pediatr Surg.* 2019;54(2):255- 257.
5. Leja M, Cine E, Rudzite D, Vilkoite I, Huttunen T, Daugule I, et al. Prevalence of *Helicobacter pylori* infection and atrophic gastritis in Latvia. *Eur J Gastroenterol Hepatol.* 2012;24:1410–1417. [PubMed] [Google Scholar]
6. Shabrawy RM, Gharib K. *Helicobacter pylori* Infection as a Risk Factor in Patients Suffering from Food Allergy and Urticaria. *Egypt J Immunol.* 2016;23(1):67-75.
7. Isaeva GS, Fagoonee S. Biological properties and pathogenicity factors of *Helicobacter pylori*. *Minerva Gastroenterol Dietol.* 2018;64(3):255-266. doi:10.23736/S1121-421X.18.02479-0
8. Camilo V, Sugiyama T, Touati E. Pathogenesis of *Helicobacter pylori* infection. *Helicobacter.* 2017;22 Suppl 1:10.1111/hel.12405. doi:10.1111/hel.12405
9. Kyburz A, Urban S, Altobelli A, et al. *Helicobacter pylori* and its secreted immunomodulator VacA protect against anaphylaxis in experimental models of food allergy. *Clin Exp Allergy.* 2017;47(10):1331-1341. doi:10.1111/cea.12996
10. Molina-Infante J, Gutierrez-Junquera C, Savarino E, Penagini R, Upper GI Tract Study Group from the Spanish Gastroenterological Association (AEG). *Helicobacter pylori* infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. *Am J Gastroenterol* 2018; [Epub ahead of print][PMID: 29545632 DOI: 10.1038/s41395-018-0035-6]
11. de Korwin JD, Ianiro G, Gibiino G, Gasbarrini A. *Helicobacter pylori* infection and extragastric diseases in 2017. *Helicobacter.* 2017;22 Suppl 1:10.1111/hel.12411. doi:10.1111/hel.12411
12. Lionetti E, Leonardi S, Lanzafame A, Garozzo MT, Filippelli M, Tomarchio S, et al. *Helicobacter pylori* infection and atopic diseases: is there a relationship? A systematic review and meta-analysis. *World J Gastroenterol.* 2014;20:17635–17647. [PMC free article] [PubMed] [Google Scholar]
13. Wang Q, Yu C, Sun Y. The association between asthma and *Helicobacter pylori*: a meta-analysis. *Helicobacter.* 2013;18:41–53. [PubMed] [Google Scholar]

14. Zhou X, Wu J, Zhang G. Association between *Helicobacter pylori* and asthma: a meta-analysis. *Eur J Gastroenterol Hepatol.* 2013;25:460–468. [PubMed] [Google Scholar]
15. Alvarez MC, Fernandes J, Michel V, Touati E, Ribeiro ML. Effect of *Helicobacter pylori* infection on GATA-5 and TFF1 regulation, comparison between pediatric and adult patients. *Dig Dis Sci.* 2018;63(11):2889- 2897.
16. Chen Y, Wang X, Yu Y, et al. Serum exosomes of chronic gastritis patients infected with *Helicobacter pylori* mediate IL-1 α expression via IL-6 trans-signalling in gastric epithelial cells. *Clin Exp Immunol.* 2018;194(3):339- 349.
17. Shabrawy RM, Gharib K. *Helicobacter pylori* Infection as a Risk Factor in Patients Suffering from Food Allergy and Urticaria. *Egypt J Immunol.* 2016;23(1):67-75
18. Food Allergy and Anaphylaxis Guidelines. EAACI. 2014. 278 p. [updated 2016 Oct 1; cited 2017 May 26]. Available from : <http://www.eaaci.org/resources/guidelines/faa-guidelines.html>
19. Aripova T. U., Musakhodzhaeva D. A., Shoazizov N. N., & Dzhumaeva D. N. (2017). Immunomodulatory effect of polyoxidonium in frequently ill children. *Medical Immunology*, 19 (S), 240-240.
20. Navruzova Sh. I., Ganieva Sh. Sh. (2019). Parameters of the immune status in gastrointestinal pathology in children. *Journal of Biomedicine and Practice* 2019, vol. 2, issue 5, pp. 64-70 <http://dx.doi.org/10.26739/2181-9300-2019-5-8>
21. Lee SY. Future candidates for indications of *Helicobacter pylori* eradication: do the indications need to be revised? *J Gastroenterol. Hepatol* 2012;27:200–11.
22. Sang Pyo Lee,* Sun-Young Lee,* Correlation Between *Helicobacter pylori* Infection, IgE Hypersensitivity, and Allergic Disease in Korean Adults 2014 *Helicobacter* ISSN 1523-5378 doi: 10.1111/hel.12173
23. Mazurina S.A., Il'inceva N.V., Agafonov V.E., Gervazieva V.B. Antihelikobakternye IgE antitela u detej s zabolevaniyami gastroduodenal'noj zony i soputstvuyushchej allergopatologiej Eksperimental'naya i klinicheskaya gastroenterologiya №9, 2013 s21-25
24. Caubet JC, Szajewska H, Shamir R, Nowak-Węgrzyn A. Non-IgE-mediated gastrointestinal food allergies in children. *Pediatr Allergy Immunol.* 2017;28(1):6-17. doi:10.1111/pai.12659]
25. Ganieva Sh.Sh., Navruzova Sh.I. Immunological features of *Helicobacter pylori* associated gastrointestinal food allergy in children. *European Journal of Biomedical and Pharmaceutical sciences.* 2020; *Volume 7, Issue 6, 131-134*
26. Razavi A, Bagheri N, Azadegan-Dehkordi F, et al. Comparative Immune Response in Children and Adults with *H. pylori* Infection. *J Immunol Res.* 2015;2015:315957. doi:10.1155/2015/315957
27. Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. *Helicobacter pylori* and extragastric diseases: A review. *World J Gastroenterol.* 2018;24:3204-3221. [PubMed] [DOI]

28. D'Elis MM, de Bernard M. To treat or not to treat *Helicobacter pylori* to benefit asthma patients. *Expert Rev Respir Med* 2010; 4: 147-150 [PMID: 20406078 DOI: 10.1586/ers.10.9]

29. Hussain K, Letley DP, Greenaway AB, Kenefick R, Winter JA, Tomlinson W, et al. *Helicobacter pylori*-Mediated Protection from Allergy Is Associated with IL-10-Secreting Peripheral Blood Regulatory T Cells. *Frontiers in immunology*. 2016;7:71.

30. Daugule I, Zavoronkova J, Santare D. *Helicobacter pylori* and allergy: update of research. *World J Methodol*. 2015;5:203–211. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

31. [Daugule I](#), [Karklina D](#), [Remberga S](#). *Pediatr Gastroenterol Hepatol Nutr*. 2017 Dec; 20(4): 216–221. Published online 2017 Dec 22. doi: [10.5223/pghn.2017.20.4.216](#) PMID: [29302502](#)

Helicobacter pylori Infection and Risk Factors in Relation to Allergy in Children

32. Borovik T.E., Makarova S.G., YAcyk G.V. m dr., Rol' narushenij bar'ernoj funkcii kishechnika v razvitii pishchevoj allergii u detej VOPROSY SOVREMENNOJ PEDIATRII /2013/ TOM 12/ № 2 s 12-19

33. Taye B, Enquselassie F, Tsegaye A, et al. Association between infection with *Helicobacter pylori* and atopy in young Ethiopian children: A longitudinal study. *Clin Exp Allergy*. 2017;47(10):1299-1308. doi:10.1111/cea.12995

34. Snovskaya M.A., Batyrova A.S., Namazova-Baranova L.S., Alekseeva A.A., Vishnyova E.A., Kozhevnikova O.V., Marushina A.A., Lubov V.N. O minimizacii zatrat na vysokoeffektivnuyu diagnostiku allergii u detej: analiz soglasovannosti rezul'tatov allergologicheskogo in vitro- i in vivo-obsledovaniya. *Vestnik RAMN*. 2015; 70 (6): 748–755. Doi: [10.15690/vramn583](#))

35. Hasosah M. Accuracy of invasive and noninvasive methods of *Helicobacter pylori* infection diagnosis in Saudi children. *Saudi J Gastroenterol*. 2019;25(2):126-131.

36. Navruzova Sh. I. Ganieva Sh. Sh., Jurayeva F. R. Diagnostic Value of Immuno-Biochemical Tests for Gastrointestinal Allergies in Children. *American Journal of Medicine and Medical Sciences*. 2020; 10(11): 901-904 DOI: [10.5923/j.ajmms.20201011.14](#)